focus -WSS

focus

author：fashion 2025-10-02 00:24:24 - browse：6595

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： STAT series 'Denied by AI' wins major journalism prizes

focus

hotspot

WSS

Long Covid research funding gets a major boost from NIH

Oak Street deal isn't the answer to health care's woes

Ripples from Flovent's discontinuation is killing children with asthma

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Long Covid research funding gets a major boost from NIH

AMAs digital advisors table RPM coding reform proposal, again

hotspot

focus

Wikipedia

Virginia high school admissions case could be legal follow

Why don't Americans have at

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Peter Hotez and the public health issue of online harassment

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

BioMarin wins approval for gene therapy to treat hemophilia A

Lilly’s weekly insulin works as well as daily products, new studies show

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

hotspot

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Tome Biosciences co

Why don't Americans have at

Supreme Court to hear if Covid misinformation is protected speech

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

leisure time

focus

hotspot

Wikipedia